Clinical Trials Logo

Clinical Trial Summary

Group A will be training group and group B will be control group. Deep breathing exercises will be done as baseline treatment in both groups. Both groups will be assessed with Modified Borg scale, 6-PBRT and Fatigue severity scale at the baseline. The control group patients will perform functional active alternating movements for the upper limbs at home involving three sets with 10 repetitions and a rest interval between 1- and 2-minute. Intervention will be for 3 times a week or 6 weeks. The treatment group patients will perform upper extremity aerobic exercises by using an arm ergometer under the supervision of a physiotherapist. Training intensity will adjust according to 50 80 % of max HR or intensity of dyspnea to 4 points on modified Borg scale (MBS) for at least 15 45 min, 3 times/week over 6 weeks.


Clinical Trial Description

Group A will be training group and group B will be control group. Deep breathing exercises will be done as baseline treatment in both groups. Both groups will be assessed with Modified Borg scale, 6-PBRT and Fatigue severity scale at the baseline. The control group patients will perform functional active alternating movements for the upper limbs at home involving three sets with 10 repetitions and a rest interval between 1- and 2-minute. Intervention will be for 3 times a week or 6 weeks. The treatment group patients will perform upper extremity aerobic exercises by using an arm ergometer under the supervision of a physiotherapist. Training intensity will adjust according to 50 80 % of max HR or intensity of dyspnea to 4 points on modified Borg scale (MBS) for at least 15 45 min, 3 times/week over 6 weeks. This study will measure and record HR by using the heart rate monitor, oxygen saturation (SpO2) by using pulse oximetry and blood pressure, breathing frequency (BF), dyspnea, fatigue, and arm fatigue by using MBS before, during, and after training. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05947240
Study type Interventional
Source Riphah International University
Contact
Status Completed
Phase N/A
Start date June 15, 2023
Completion date December 15, 2023

See also
  Status Clinical Trial Phase
Completed NCT03145298 - ALlogeneic Cardiosphere-derived Stem Cells (CDCs) for Pulmonary Hypertension therApy Phase 1
Recruiting NCT03362047 - (RIGHT HEART III Study - Right Ventricular Hemodynamic Evaluation and Response to Treatment) Phase 2
Recruiting NCT03235401 - The PAH Disability and Bothersomeness Questionnaire N/A
Recruiting NCT01347216 - COMPERA / COMPERA-KIDS
Completed NCT05546125 - a Non-interventional Study of Sildenafil in the Treatment of Pulmonary Arterial Hypertension (PAH) in Adults From China
Terminated NCT00586794 - Therapy of Pulmonary Arterial Hypertension (PAH) - Treatment With Sildenafil in Eisenmenger Patients Phase 3
Completed NCT03523910 - Right Ventricular Pulmonary Vascular Interaction in Pulmonary Hypertension N/A